Abstract-The tune course of liver phosphorylase activation after catecholamine administration and the relative abilities of several adrenergic blocking agents to block catecholamine-induced phosphorylase activation in liver and skeletal muscle was studied in intact anesthetized rats. Subcutaneously injected epinephrine and norepinephrine increased the liver phosphorylase activity, the peak effect occurring 10 min after injection. The liver phosphorylase levels were somewhat reduced 30 min after injection. Isoproterenol administration did not increase the level of rat liver phosphorylase. Blood glucose changes after catecholamine treatment did not mirror the changes in liver phosphorylase activity.
THE
blood glucose elevation, liver phosphorylase activation, and glycogenolysis induced by the catecholamines have been extensively investigated.lp2 Although the phosphorylase response has been reported consistently for liver slices in vitro, an effect in z'iro after catecholamine administration has been both confirmed and denied.3-5 The effect of adrenergic blocking agents on liver phosphorylase activation after catecholamine administration has not been clarified.6 Phosphorylase activation in skeletal muscle after catecholamine administration is well documented;',* however, no data could be found demonstrating the nature of this response after adrenergic blocking agents.
The present investigation will be concerned with the time-response relationships of phosphorylase activation and blood glucose levels in rat liver after the administration of L-epinephrine, L-norepinephrine, and DL-isoproterenol and the susceptibility of epinephrine-induced activation of liver and skeletal muscle phosphorylase to adrenergic blockade.
METHODS
White female rats (180 to 200 g, Holtzman strain) were used throughout the investigation.
Rats were maintained on food at all times. Anesthesia was produced by the intraperitoneal injection of hexobarbital sodium (150 to 180 mg/kg) 10 min before sacrifice or catecholamine infusion. Lab.) were diluted in a 0.9:; NaCI-0.1 y,,, NaNSO,, solution to obtain the proper col~celltratio~l for injection. The time.-response curves \vere determined after subcutaneous injection of the catecholamine (500 t~,g/kg). The intravenous infusion of L-epinephrine (0.25 pg/kg.min--l for IO min) \vas accomplished a5 described previously."
The tissues nere excised rapidly from anesthetized animals and frozen in beakers of isopentane cooled in alcohol-dry ice. The liver was excised before the skeletal muscle in all experiments.
Phosphorylase and glycogen were assayed as previously reported.!' The liver sample was diluted such that an equivalent of 5 mg wet \\eight of liver (I :200 dilution) was assayed. 
RESULTS
Sacrifice by decapitation markedly activated liver phosphorylase ( Table 1) even it the animal was pre\Gously anesthetized.
For this reason decapitati~~rl \ias avoided, and tissue samples were obtained under surgical anesthesia. Table 2 gives the liver phosphory~ase and blood glucose responses after subcutaneoLls L-epinephrine.
I.-norepinephrine, and Dr.-isoproterenol administration. L-Epinephrine injection caused an activation of liver phosphorylase which was maximal at 10 min after injection. In contrast to the, phosphorylase response, the blood glucose levels after epinephrine administration showed a steady rise throughout the sampling period. Blood glucose determinations at 60 min after epinephrine injection were somewhat higher than those found at 30 min (unpublished observations). L-Norepinephrine injection produced liver phosphorylase activation similar to that observed after epinephrine administration;
however the blood glucose elevation was neither so rapid (6) 3.6x1.2(6) 3.6*0.4 (7) 4.8 i~O.9 (6) 5.1+0,8 (7) 4.6~0.6 (7) 5.5 +0.9 (5) Blood glucose (:/ over control) 23 =2 (9) 33'9 (9) 58+12 (9) 90+9 (13) 8112 (3) 6-i 17 (3) 48 12 (3) 47 lr34 (3) I15 (7) 9_t IO (7) 22'12 (7) 49+13 (7) * All catecholamines given subcutaneously (500 rg/kg).
Values are means &SE. Numbers of animals per treatment are in parentheses. t Significantly different from control (P < 0.05).
nor so marked as that observed after epinephrine injection. or_-Tsoproterenol elicited no statistically significant increase in liver phosphorylase levels at all times measured. and only the 30-min blood glucose sample was significantly higher than control levels,
The influence of adrenergic blockade on liter and skeletal muscle phosphorylase actil;ation by atecholamines
The data in Table 3 show that L-epinephrine infusion, 0.25pg/kg.min-l intravenously, for 10 min, elicited an increase in active phosphorylase levels in both liver and skeletal muscle. (Table 3) . DC1 treatment produced no activation of liver phosphorylase with the dose of either 10 or 25 mg/kg. At both DC1 dose levels, partial to complete blockade of the liver response to epinephrine infusion was observed.
Treatment with nethalide (ICI-38, 174), a p-adrenergic blocking agent with no demonstrable sympathomimetic action,rl produced a complete blockade of the epinephrine-induced phosphorylase activation in skeletal muscle and a partial inhibition of the epinephrine effect on liver phosphorylase. Ergotamine did not significantly affect the skeletal muscle phosphorylase response to epinephrine but did effectively prevent the liver phosphorylase response to epinephrine infusion.
Phenoxybenzamine treatment (5 or 20 mg/kg) did not influence the skeletal muscle phosphorylase response to epinephrine but partially reduced the increase in liver phosphorylase produced by epinephrine. In contrast to DC1 and nethalide, only a moderate blockade of the epinephrine response was observed in all animals at both dose levels of phenoxybenzamine.
Treatment of the animal with both phenoxybenzamine and DC1 prior to epinephrine infusion produced more blockade of the epinephrine-induced liver phosphorylase response than that observed after phenoxybenzamine treatment but was not significantly different from the blockade observed after DC1 treatment. The skeletal muscle phosphorylase response to epinephrine after the combination blockade was not significantly different from that obtained with DC1 treatment alone.
Prior treatment of the rat with hexamethonium (IO mg/kg) produced no significant change in either the skeletal muscle or liver phosphorylase response to epinephrine infusion.
The skeletal muscle phosphorylase response to epinephrine in the second group of Table 3 is somewhat lower than the epinephrine responses observed in the other two groups, whereas the liver phosphorylase responses to epinephrine in all groups are similar. An explanation for this difference is not apparent.
DISCUSSION
The mechanism of the catecholamine-induced activation of glycogen phosphorylase has been extensively investigated by Sutherland and his co-workers. In recent reports they have indicated that the catecholamine effect is an indirect one mediated through an accumulation of cyclic 3', 5' adenosine monophosphate, which then stimulates the formation of active phosphorylase kinase. This enzyme catalyses the conversion of inactive to active phosphorylase. 1?2-14 The applicability of this system to liver and skeletal muscle has been demonstrated. 13, 15 The activation of liver phosphorylase by the catecholamines has been demonstrated conclusively in the liver slice of several species. 3~16s17 Liver phosphorylase activation after catecholamine administration in vivo has been observed in the rabbit3 but not in the rat.S,5s18 The present data indicate that, with an adequate dose of catecholamine, rat liver phosphorylase activation can be obtained in vivo. Although the dose of catecholamine was larger than that used by other investigators, the method of sacrifice
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of the animal and the time of sampling appear to be as important as the dose of catechoiamine employed to demonstrate liver phosphorylase activation.
In the investigations mentioned above in which no liver phosphorylase activation was observed after epinephrine administration, the control phosphorylase levels reported were in the range of 9 to IO PM inorganic phosphate/g*min-'9 1, 5, I'(. This is somewhat higher than the control values (2.8 to 4.9pM inorganic phosphate/g.minm I) reported in the present investigation and may be sufficiently high so that an epinephrine-induced activation M,ould be masked. Also, in the investigations in \vhich phosphorylase activation could not be demonstrated after epinephrine administration, tissue samples were not usually taken before 30 min after epinephrine injection. AS may be seen in Table 2 . at this time a considerable portion of the catecholamineinduced phosphorylase activation was dissipated.
The problem of \vhal constitutes a ";easonable" control phosphorylase value for liver has not been extensively discussed. It has been generally found that liver slices have lower phosphorylase levels than those values obtained after tissue sampling in r*ir.o." An exact level of active liver phosphorylase as a percentage of the total enzyme present is difficult to determine because inactive liver phosphorylase is not stimulated to activity by the addition of adenosine monophosphate.]" From our data with epinephrine stimulation of rat liver phosphorylase, it appears that the total liver phosphorylase activity is in the range of 15 to 20 PM inorganic phosphate/g.min 1 assayed at 30 . If it is further assumed that the active liver phosphorylase is present in I.;PO in the same relationship to total enzyme content as occurs in heart and skeletal muscle (0 to I2 % active phosphorylase), 15~1",'Ln then the control liver phosphorylase levels in ciao would be approximately 0.0 to 2.4 PM inorganic phosphate/g.min~~'. Our control values for liver phosphorylase in riro approach this range. Cornblathl" has reported liver phosphorylase values of this magnitude for rabbit liver slices itz l.itro. Other investigators using both in-vitro" and in-riro sampling3.5.1H have reported higher control phosphorylase levels for rat liver. A possible explanation for some of these differences in control phosphorylase levels may be that a conversion of inactive phosphorylase to active phosphorylase occurs after excision of the liver even though the tissue is maintained at 0 ~. A similar conversion of inactive to active phosphorylase during homogenization has been reported for skeletal musclel!' and heart" samples.
The relative potencies of the catecholamines for rat liver phosphorylase activation in riro appear to be L-epinephrine :-L-norepinephrine > oL-isoproterenol. This ordel of potency has also been observed for the hyperglycemic response to catecholamines in the intact rat21 and glucose production by rat liver slices.' L2 A different order of potency for glycogen mobilization has been previously determined for rat heart" ( I :y E NE) and rat skeletal muscle2" (E Y, I '> NE). Mayer et al." determined that catecholamine potency ratios for hyperglycemia in the intact dog are I A-E :; NE. A similar order of catecholamine potency was reported by Sutherland and Rail' for phosphorylase activation in dog liver homogenate and by Murad et al. 13 for cyclic 3', 5'-adenosine monophosphate production in the washed particulate fraction of dog liver. It would therefore appear, on the basis of sensitivity of the liver phosporylase activation to catecholamines, that a considerable species difference exists between the adrenergic receptor of the rat and dog liver. The insensitivity of rat liver phosphorylase to isoproterenol administration is further demonstrated by the fact that the dose used in this investigation is ten times higher than that necessary to produce a marked activation of heart and skeletal muscle phosphorylase.s
The time course of the liver phosphorylase activation after subcutaneous catecholamine administration is different from that observed in rat heart and skeletal muscle.g In the latter tissues, peak phosphorylase activation occurred at 5 min or earlier after catecholamine injection. In the liver, peak phosphorylase activation did not occur until 10 min after injection and was decreased 30 min after injection. In contrast to heart and skeletal muscle phosphorylase, the liver phosphorylase time-response curve did not parallel the plasma epinephrine level which we have previously reported to be maintained at a relatively constant concentration (approximately 9 pg/l) from 5 to 60 min after a subcutaneous epinephrine injection of 500 pg/kg.y An explanation for this delayed response in the liver is not apparent. Tt is possible that catecholamineinduced vascular changes in the liver altered the drug distribution pattern leading to a gradual rise in the concentration of the catecholamine at the receptor site. The relationship of the blood glucose changes to the alteration in liver phosphorylase after catecholamine administration suggest that a change in blood glucose is not indicative of the degree or duration of a liver phosphorylase response. In fact, the blood glucose level after epinephrine injection was still increasing at 1 hr after epinephrine, even though the phosphorylase activity had declined somewhat at 30 min. In addition, the blood glucose responses to norepinephrine and isoproterenol did not mirror the responses of liver phosphorylase.
Cahill et al. 21 have reported a similar lack of correlation between liver phosphorylase activation and blood glucose changes after glucagon infusion in the dog.
The classification of the liver phosphorylase response to epinephrine as either an aor p-or both an a-and fi-adrenergic receptor appears to be somewhat difficult. The inability of phenoxybenzamine to cause more than a partial reduction in the epinephrine-induced increase in liver phosphorylase, whereas ergotamine completely abolished the response, suggests that the usual a-adrenergic receptor is not involved in the epinephrine action. Harvey et a1. 25 reached a similar conclusion based upon the dissociation between the relative abilities of phenoxybenzamine and ergotamine to block the vasoconstrictor response and the hyperglycemia observed after epinephrine administration.
In addition, the liver phosphorylase response was reduced by the /3-adrenergic blocking agents, DC1 and nethalide. Both of these compounds caused a partial, and in several animals a complete, blockade of the rat liver phosphorylase response to epinephrine.
Treatment with both a-and p-receptor blocking agents did not aid in defining the nature of the liver adrenergic receptor. Although the catecholamine potency ratio for rat liver phosphorylase activation in ciao (E > NE > I) fits that order postulated by FurchgotP necessary to define an a-adrenergic receptor, we do not feel that a definite classification can be determined at this time.
The experiments with hexamethonium treatment demonstrate that depression of the automatic nervous system, at a site other than the postganglionic adrenergic receptor, does not alter the epinephrine-induced liver phosphorylase activation. The phorphorylase data presented above for the interaction of adrenergic blocking agents with epinephrine is in general agreement with the data of Kennedy and Ellis,2' who measured tissue glycogen levels after epinephrine administration and a-and /3-adrenergic blocking agents.
